TransCode Therapeutics, Inc. develops RNA and immuno-oncology therapeutics for high-risk and advanced cancers. News about RNAZ centers on its lead candidate TTX-MC138, an antagomiR targeting microRNA-10b, along with preclinical publications, IND-related clinical updates, research collaborations and sponsored research tied to RNA-targeted oncology.
Company updates also cover additions to its early-stage oncology pipeline, including adenovirus-based oncolytic immunotherapy candidates UIO-524, UIO-525 and UIO-526, as well as governance changes involving its board and scientific advisory structure. Capital-structure announcements, material agreements and operating or financial results are recurring disclosure themes for this clinical-stage biotechnology issuer.
Natera (NTRA) and TransCode Therapeutics (RNAZ) announced a colorectal cancer collaboration supporting enrollment in TransCode’s Phase 2a trial of TTX-MC138.
TransCode will use Natera’s Signatera test to identify eligible patients who have completed curative-intent therapy but remain positive for molecular residual disease, meaning molecular evidence of remaining cancer, with no disease visible on imaging. The companies aim to improve patient identification and enrollment. Quantum Leap Healthcare Collaborative is conducting the study within its PRE-I-SPY program, marking the program’s first expansion beyond breast cancer into colorectal cancer.
TransCode Therapeutics (RNAZ) reported updated Phase 1a TTX-MC138 findings, with 10 of 14 efficacy-evaluable patients achieving stable disease.
At the September 1, 2026, cutoff, investigator assessments showed a 71.4% stable disease rate. Disease control was 57.1% at Cycle 3 Day 1, and three patients were progression-free at 12 months. In a post-hoc comparison with prior therapy, six of 15 evaluable patients had a growth modulation index above 1.3.
The study met its primary endpoint. No dose-limiting toxicities or treatment-emergent adverse events leading to discontinuation were reported across evaluated doses, including 4.8 mg/kg. Exploratory blood RNA sequencing found treatment-associated immune activity, but the small sample requires confirmation in larger studies. TransCode is evaluating dose-expansion strategies and expects to add the findings to its clinical study report.
TransCode Therapeutics (RNAZ) reported new patent milestones in Australia and Japan that expand protection for its RNA-based immuno-oncology platform.
IP Australia issued a Notice of Acceptance for Patent Application No. 2019349817, covering iron oxide core, dextran-coated nanoparticles covalently linked to siRNA, related pharmaceutical compositions, and methods to treat multiple cancers, including colon, lung, breast, pancreatic, and ovarian cancers. In Japan, the Japan Patent Office granted Patent No. 7886877 for RNA-based immunomodulatory compositions, including 5′ triphosphate-modified RNA oligonucleotides designed to activate innate immune pathways such as RIG-I within tumors. The Australian patent application is expected to proceed to grant with a projected expiry of September 6, 2039, further strengthening TransCode’s global IP estate, including coverage around candidates such as TTX-MC138.
TransCode Therapeutics (RNAZ) announced that Chief Financial Officer and director Tom Fitzgerald has retired and resigned from his roles, effective immediately, on September 10, 2026.
Fitzgerald, who has served as CFO since July 2018, helped guide the company through its initial public offering, the launch of its clinical program for lead candidate TTX-MC138, and its acquisition of Polynoma and license agreement with Oncolytics, which expanded its oncology pipeline. He will continue to provide transition services to the company. John Tattory, a senior finance executive with over 25 years of experience in life sciences, including prior CFO roles and capital-raising responsibilities, has been appointed Interim Chief Financial Officer, effective immediately.
TransCode Therapeutics (NASDAQ: RNAZ) reported publication of a peer-reviewed study in Cancers showing its lead candidate TTX-MC138 produced significant survival benefits in a preclinical mouse model of breast cancer bone metastasis. According to TransCode, systemically administered TTX-MC138 accumulated in metastatic bone lesions, reduced expression of metastasis‑linked microRNA‑10b (miR‑10b), and increased expression of the tumor‑suppressor target HOXD10.
The study also found repeated dosing was well tolerated with no observed systemic toxicity, supporting the use of image‑guided anti‑miR‑10b nanotherapeutics as a potentially translatable approach for metastatic cancer. TransCode said the findings may inform future applications beyond its current clinical focus in colorectal cancer.
TransCode Therapeutics (NASDAQ: RNAZ) will host its first live virtual R&D webcast on June 18, 2026, at 10:00–11:15 a.m. Eastern Time. The event will highlight the TTX-MC138 Phase 2a trial in ctDNA-positive colorectal cancer, its three-platform RNA and immuno-oncology pipeline, and overall investment thesis.
The webcast is open access, with registration available on the company website from June 11, 2026. A replay will be posted online after the event.
TransCode Therapeutics (NASDAQ: RNAZ) reported final Phase 1a data for TTX-MC138 in metastatic cancer. The dose-escalation trial met its primary safety endpoint with no dose-limiting toxicities across 16 patients and 86 doses up to 4.8mg/kg.
Median treatment lasted 11.3 weeks; three patients remain on therapy. At least 9 of 14 evaluable patients (64%) achieved stable disease lasting six months based on RECIST criteria. TransCode selected 4.8mg/kg as the recommended Phase 2a dose and is advancing TTX-MC138 into a Phase 2a trial in ctDNA-positive colorectal cancer after curative-intent therapy.
TransCode Therapeutics (NASDAQ: RNAZ) initiated a Phase 2a trial of lead candidate TTX‑MC138 in patients with ctDNA‑positive colorectal cancer after curative‑intent therapy and no radiographic disease. The study, in collaboration with Quantum Leap Healthcare Collaborative’s PRE‑I‑SPY platform, plans to enroll up to 45 patients.
The FDA‑submitted, IRB‑approved trial uses leading NCCN centers to assess TTX‑MC138’s biological and clinical activity in minimal residual disease, building on Phase 1a safety and durable anti‑tumor effects reported by TransCode.
TransCode Therapeutics (NASDAQ: RNAZ) appointed Anna Moore, PhD as Chair of its Scientific Advisory Board and signed a sponsored research agreement (SRA) with Michigan State University on April 27, 2026. Dr. Moore is a TransCode co-founder and will guide R&D, including work on lead candidate TTX-MC138.
The SRA will support preclinical and translational studies to accelerate pipeline candidates into clinical development, including evaluation of TTX-MC138 combined with Seviprotimut-L and standard-of-care therapies.
TransCode Therapeutics (NASDAQ: RNAZ) entered agreements for up to $20 million in flexible financing on April 7, 2026, combining up to $6 million in pre-paid advances and a three-year SEPA to sell up to $14 million of common stock subject to conditions.
Management says the financing extends the company runway into late 2027/early 2028 and is intended to support completion of the Phase 2a trial for lead program TTX-MC138 and exploration of a strategic collaboration.